Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer

Keizo Sugimachi, Yoshihiko Maehara, Michio Ogawa, Teruo Kakegawa, Masao Tomita

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

A retrospective analysis of postoperative chemotherapy had shown the continuous administration of UFT, an oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil at a molar ratio of 1:4, to be effective for poorly differentiated gastric cancer. We therefore sought to determine prospectively the effective dose of postoperative chemotherapy with UFT for patients with poorly differentiated gastric cancer following a curative resection. We determined the effect of the combined intravenous administration of mitomycin C (MMC) and oral treatment with protein-bound polysaccharide Kreha (PSK), extracted from the basidiomycete Coriolus versicolor, and UFT at a dose of either 8 mg/kg or 12 mg/kg daily for 1 year. A total of 224 patients with poorly differentiated stage II-IV gastric cancer were entered into this study after undergoing a curative resection. No differences were observed between the two treatment groups in terms of prognostic factors, the toxicity, rate or the doses of the drugs prescribed, other than UFT. The higher dose of UFT in maintenance therapy led to a decrease in the recurrence rate (P < 0.05), and increases in disease-free survival and cause-specific survival (P < 0.05). UFT at 12 mg/kg in postoperative chemotherapy was thus found- to improve the postoperative results with no increase in toxicity for poorly differentiated gastric cancer, and is also cost-effective for outpatients.

Original languageEnglish
Pages (from-to)233-238
Number of pages6
JournalCancer chemotherapy and pharmacology
Volume40
Issue number3
DOIs
Publication statusPublished - Jul 1 1997

Fingerprint

Tegafur
Chemotherapy
Uracil
Stomach Neoplasms
Drug Therapy
Toxicity
Mitomycin
Basidiomycota
Polysaccharides
Intravenous Administration
Disease-Free Survival
Oral Administration
Outpatients
Therapeutics
Costs and Cost Analysis
Recurrence
Pharmaceutical Preparations
Survival
Costs
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. / Sugimachi, Keizo; Maehara, Yoshihiko; Ogawa, Michio; Kakegawa, Teruo; Tomita, Masao.

In: Cancer chemotherapy and pharmacology, Vol. 40, No. 3, 01.07.1997, p. 233-238.

Research output: Contribution to journalArticle

Sugimachi, Keizo ; Maehara, Yoshihiko ; Ogawa, Michio ; Kakegawa, Teruo ; Tomita, Masao. / Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. In: Cancer chemotherapy and pharmacology. 1997 ; Vol. 40, No. 3. pp. 233-238.
@article{008a7ed1746f486694a8975aba32505a,
title = "Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer",
abstract = "A retrospective analysis of postoperative chemotherapy had shown the continuous administration of UFT, an oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil at a molar ratio of 1:4, to be effective for poorly differentiated gastric cancer. We therefore sought to determine prospectively the effective dose of postoperative chemotherapy with UFT for patients with poorly differentiated gastric cancer following a curative resection. We determined the effect of the combined intravenous administration of mitomycin C (MMC) and oral treatment with protein-bound polysaccharide Kreha (PSK), extracted from the basidiomycete Coriolus versicolor, and UFT at a dose of either 8 mg/kg or 12 mg/kg daily for 1 year. A total of 224 patients with poorly differentiated stage II-IV gastric cancer were entered into this study after undergoing a curative resection. No differences were observed between the two treatment groups in terms of prognostic factors, the toxicity, rate or the doses of the drugs prescribed, other than UFT. The higher dose of UFT in maintenance therapy led to a decrease in the recurrence rate (P < 0.05), and increases in disease-free survival and cause-specific survival (P < 0.05). UFT at 12 mg/kg in postoperative chemotherapy was thus found- to improve the postoperative results with no increase in toxicity for poorly differentiated gastric cancer, and is also cost-effective for outpatients.",
author = "Keizo Sugimachi and Yoshihiko Maehara and Michio Ogawa and Teruo Kakegawa and Masao Tomita",
year = "1997",
month = "7",
day = "1",
doi = "10.1007/s002800050652",
language = "English",
volume = "40",
pages = "233--238",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer

AU - Sugimachi, Keizo

AU - Maehara, Yoshihiko

AU - Ogawa, Michio

AU - Kakegawa, Teruo

AU - Tomita, Masao

PY - 1997/7/1

Y1 - 1997/7/1

N2 - A retrospective analysis of postoperative chemotherapy had shown the continuous administration of UFT, an oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil at a molar ratio of 1:4, to be effective for poorly differentiated gastric cancer. We therefore sought to determine prospectively the effective dose of postoperative chemotherapy with UFT for patients with poorly differentiated gastric cancer following a curative resection. We determined the effect of the combined intravenous administration of mitomycin C (MMC) and oral treatment with protein-bound polysaccharide Kreha (PSK), extracted from the basidiomycete Coriolus versicolor, and UFT at a dose of either 8 mg/kg or 12 mg/kg daily for 1 year. A total of 224 patients with poorly differentiated stage II-IV gastric cancer were entered into this study after undergoing a curative resection. No differences were observed between the two treatment groups in terms of prognostic factors, the toxicity, rate or the doses of the drugs prescribed, other than UFT. The higher dose of UFT in maintenance therapy led to a decrease in the recurrence rate (P < 0.05), and increases in disease-free survival and cause-specific survival (P < 0.05). UFT at 12 mg/kg in postoperative chemotherapy was thus found- to improve the postoperative results with no increase in toxicity for poorly differentiated gastric cancer, and is also cost-effective for outpatients.

AB - A retrospective analysis of postoperative chemotherapy had shown the continuous administration of UFT, an oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil at a molar ratio of 1:4, to be effective for poorly differentiated gastric cancer. We therefore sought to determine prospectively the effective dose of postoperative chemotherapy with UFT for patients with poorly differentiated gastric cancer following a curative resection. We determined the effect of the combined intravenous administration of mitomycin C (MMC) and oral treatment with protein-bound polysaccharide Kreha (PSK), extracted from the basidiomycete Coriolus versicolor, and UFT at a dose of either 8 mg/kg or 12 mg/kg daily for 1 year. A total of 224 patients with poorly differentiated stage II-IV gastric cancer were entered into this study after undergoing a curative resection. No differences were observed between the two treatment groups in terms of prognostic factors, the toxicity, rate or the doses of the drugs prescribed, other than UFT. The higher dose of UFT in maintenance therapy led to a decrease in the recurrence rate (P < 0.05), and increases in disease-free survival and cause-specific survival (P < 0.05). UFT at 12 mg/kg in postoperative chemotherapy was thus found- to improve the postoperative results with no increase in toxicity for poorly differentiated gastric cancer, and is also cost-effective for outpatients.

UR - http://www.scopus.com/inward/record.url?scp=0030952183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030952183&partnerID=8YFLogxK

U2 - 10.1007/s002800050652

DO - 10.1007/s002800050652

M3 - Article

C2 - 9219507

AN - SCOPUS:0030952183

VL - 40

SP - 233

EP - 238

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -